Drugs for Pain | The Medical Letter Inc.

Treatment Guidelines from The Medical Letter

FROM
ISSUE

128

April 1, 2013

View Complete Issue Table of Contents 2019

Drugs for Pain

Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article.

Drugs for Pain

April 1, 2013 (Issue: 128)

Superseded by The Medical Letter "Nonopioid Drugs for Pain" - Issue 1645, March 7, 2022
Superseded by The Medical Letter "Opioids for Pain" - Issue 1665, December 12, 2022

Pain can be acute or chronic. The two major types of chronic pain are nociceptive pain and neuropathic pain. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids and is often treated...more

Show References Hide References

1. Intravenous acetaminophen (Ofirmev). Med Lett Drugs Ther 2011; 53:26.

2. Acetaminophen safety - Deja vu. Med Lett Drugs Ther 2009; 51:53.

3. PB Watkins et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006; 296:87.

4. Addendum: warfarin-acetaminophen interaction. Med Lett Drugs Ther 2008; 50:45.

5. In brief: does acetaminophen increase blood pressure? Med Lett Drugs Ther 2011; 53:29.

6. PL McCormack. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs 2011; 71:2457.

7. Primary prevention of ulcers in patients taking aspirin or NSAIDs. Med Lett Drugs Ther 2010; 52:17.

8. Naproxen/esomeprazole (Vimovo). Med Lett Drugs Ther 2010; 52:74.

9. A fixed-dose combination of ibuprofen and famotidine (Duexis). Med Lett Drugs Ther 2011; 53:85.

10. S Trelle et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342:c7086.

11. P McGettigan and D Henry. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011; 8:e1001098.

12. ME Farkouh and BP Greenberg. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 2009; 103:1227.

13. WB White et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol 2007; 99:91.

14. EM Antman et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007; 115:1634.

15. E Cho et al. Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med 2011; 171:1487.

16. CM Reid et al. Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials. Arch Intern Med 2006; 166:837.

17. TJ Cicero et al. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 2012; 367:187.

18. In brief: immediate-release oxycodone (Oxecta) for pain. Med Lett Drugs Ther 2012; 54:20.

19. Oral oxymorphone (Opana). Med Lett Drugs Ther 2007; 49:3.

20. PA Sloan and R Barkin. Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review. J Opioid Manag 2008; 4:131.

21. Extended-release hydromorphone (Exalgo) for pain. Med Lett Drugs Ther 2011; 53:62.

22. H Binsfeld et al. A randomized study to demonstrate noninferiority of once-daily OROS hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain. Pain Pract 2010; 10:404.

23. In brief: heat and transdermal fentanyl. Med Lett Drugs Ther 2009; 51:64.

24. CYP3A and drug interactions. Med Lett Drugs Ther 2005; 47:54.

25. FDA. FDA reminds the public about the potential for life-threatening harm from accidental exposure to fentanyl transdermal systems ("patches"). April 18, 2012. Available at www.fda.gov/Drugs/DrugSafety/ucm300747.htm.

26. JS Morley et al. Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial. Palliat Med 2003; 17:576.

27. MC Rowbotham et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003; 348:1223.

28. KM Foley. Opioids and chronic neuropathic pain. N Engl J Med 2003; 348:1279.

29. E Bruera et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 2004; 22:185.

30. GB Ehret et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med 2006; 166:1280.

31. MJ Krantz et al. QTc interval screening in methadone treatment. Ann Intern Med 2009; 150:387.

32. FDA. FDA Drug Safety Communication: safety review update of codeine use in children; new boxed warning and contraindication on use after tonsillectomy and /or adenoidectomy. February 20, 2013. Available at www.fda.gov/Drugs/DrugSafety/ucm339112.htm. Accessed March 7, 2013.

33. Tapentadol (Nucynta) – a new analgesic. Med Lett Drugs Ther 2009; 51:61.

34. M Afilalo and B Morlion. Efficacy of tapentadol ER for managing moderate to severe pain. Pain Physician 2013; 16:27.

35. RM Duhmke et al. Tramadol for neuropathic pain (review). Cochrane Database Syst Rev 2004; (2):CD003726.

36. Transdermal buprenorphone (Butrans) for chronic pain. Med Lett Drugs Ther 2011; 53:31.

37. Buprenorphine: an alternative to methadone. Med Lett Drugs Ther 2003; 45:13.

38. New indications for modafinil (Provigil). Med Lett Drugs Ther 2004; 46:34.

39. Methylnaltrexone (Relistor) for opioid-induced constipation. Med Lett Drugs Ther 2008; 50:63.

40. J Thomas et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008; 358:2332.

41. MJ Brennan. The effect of opioid therapy on endocrine function. Am J Med 2013; 126:S12.

42. K Bannister and AH Dickenson. Opioid hyperalgesia. Curr Opin Support Palliat Care 2010; 4:1.

43. I Gilron et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009; 374:1252.

44. W Häuser et al. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA 2009; 301:198.

45. SH Sindrup et al. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005; 96:399.

46. DR Grothe et al. Treatment of pain syndromes with venlafaxine. Pharmacotherapy 2004; 24:621.

47. Duloxetine (Cymbalta) for diabetic neuropathic pain. Med Lett Drugs Ther 2005; 47:67.

48. Duloxetine (Cymbalta) for fibromyalgia. Med Lett Drugs Ther 2008; 50:57.

49. Duloxetine (Cymbalta) for chronic musculoskeletal pain. Med Lett Drugs Ther 2011; 53:33.

50. Milnacipran (Savella) for fibromyalgia. Med Lett Drugs Ther 2009; 51:45.

51. Gabapentin (Neurontin) for chronic pain. Med Lett Drugs Ther 2004; 46:29.

52. I Gilron et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005; 352:1324.

53. Pregabalin (Lyrica) for neuropathic pain and epilepsy. Med Lett Drugs Ther 2005; 47:75.

54. W Häuser et al. Treatment of fibromyalgia syndrome with gabapentin and pregabalin—a meta-analysis of randomized controlled trials. Pain 2009; 145:69.

55. Ziconotide (Prialt) for chronic pain. Med Lett Drugs Ther 2005; 47:103.

56. RY Yuan et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009; 72:1473.

57. Medical marijuana. Med Lett Drugs Ther 2010; 52:5.

58. M Karst et al. Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs 2010; 70:18.

59. PS Davies and BS Galer. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 2004; 64:937.

60. Capsaicin patch (Qutenza) for postherpetic neuralgia. Med Lett Drugs Ther 2011; 53:42.

61. FDA. FDA drug safety communication: rare cases of serious burns with the use of over-the-counter topical muscle and joint pain relievers. Available at www.fda.gov/Drugs/DrugSafety/ucm318858.htm. Accessed March 8, 2013.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.